LB Pharmaceuticals Inc (LBRX) Income Statement
LBRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLBRX revenue and net income
LBRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LBRX quarterly EPS vs estimates
LB Pharmaceuticals beat the analyst EPS estimate in 1 of the last 5 quarters. Next report: November 5, 2026 (estimate $-1.61).
LBRX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $321,000 | — | — | — |
| Gross profit | −$321,000 | — | — | — |
| Research & development | $16.7M | $51.2M | $7.8M | $1.3M |
| Sales, general & admin | $13.7M | $13.7M | $3.5M | $1.5M |
| Total operating expenses | $30.4M | $64.8M | $11.4M | $2.8M |
| Operating income | −$30.4M | −$64.8M | −$11.4M | −$2.8M |
| Interest income | $3.9M | $1.7M | $811,000 | $73,000 |
| Interest expense | — | $0 | $4.8M | $2.2M |
| Income before taxes | −$25.2M | −$63.1M | −$6.3M | −$14.3M |
| Income taxes | $1,000 | $1,000 | $1,000 | $1,000 |
| Net income | −$25.2M | −$63.1M | −$6.3M | −$14.3M |
| EBITDA | −$24.9M | −$63.0M | −$1.4M | −$12.2M |
| EPS (diluted) | −$2.50 | −$2.81 | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $97,000 | $82,000 | $85,000 | $81,000 | — | — | — | $5,000 | — | — |
| Gross profit | −$97,000 | −$82,000 | −$85,000 | −$81,000 | — | — | — | −$5,000 | — | — |
| Research & development | $44.1M | $14.6M | $8.5M | $2.4M | $2.9M | $2.9M | $376,000 | $10.7M | $24.5M | $15.7M |
| Sales, general & admin | $9.8M | $7.5M | $5.4M | $2.8M | $2.6M | $2.6M | $5.2M | $5.4M | $2.1M | $957,000 |
| Total operating expenses | $53.8M | $22.0M | $13.9M | $5.2M | $5.6M | $5.6M | $5.5M | $16.1M | $26.6M | $16.6M |
| Operating income | −$53.9M | −$22.1M | −$13.9M | −$5.2M | −$5.6M | −$5.6M | −$5.5M | −$16.1M | −$26.6M | −$16.6M |
| Interest income | $3.0M | $2.9M | $2.8M | $707,000 | $177,000 | $236,000 | $298,000 | $384,000 | $411,000 | $628,000 |
| Interest expense | — | — | — | — | $206,500 | $206,500 | — | — | — | $0 |
| Income before taxes | −$51.6M | −$19.1M | −$11.5M | −$3.6M | −$5.1M | −$5.1M | −$5.1M | −$14.2M | −$27.7M | −$16.2M |
| Income taxes | — | — | $1,000 | — | — | — | — | — | — | — |
| Net income | −$51.6M | −$19.1M | −$11.5M | −$3.6M | −$5.1M | −$5.1M | −$5.1M | −$14.2M | −$27.7M | −$16.2M |
| EBITDA | −$53.8M | −$19.0M | −$11.4M | −$3.5M | −$5.2M | −$5.2M | — | −$14.2M | −$27.1M | −$16.2M |
| EPS (diluted) | −$1.71 | −$0.67 | −$0.45 | −$0.61 | −$1.44 | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LBRX's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LBRX financial results
LB Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $25.2 million. Diluted earnings per share came to −$2.50.
See the LBRX stock overview for the latest quote and news, or the LBRX chart for price history and technical indicators.
LBRX income statement FAQ
Does LB Pharmaceuticals have revenue?
LB Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is LB Pharmaceuticals profitable?
No. LB Pharmaceuticals reported a net loss of $25.2 million in fiscal 2025.
How much does LB Pharmaceuticals spend on research and development?
LB Pharmaceuticals spent $16.7 million on research and development in fiscal 2025.
What are LB Pharmaceuticals's earnings per share?
LB Pharmaceuticals earned $-2.50 per diluted share in fiscal 2025, compared with $-2.81 a year earlier.
When will LB Pharmaceuticals report its next earnings?
LB Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does LB Pharmaceuticals's fiscal year end?
LB Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.